Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

AI Is Already Aiding Clinical Practice Across the Cancer Care Continuum

August 21st 2025

Clinicians spanning a spectrum of cancer subtypes discuss how they are currently using artificial intelligence in their daily practice.

Darolutamide Doublet Is Redefining Treatment Decision-Making for mCSPC

August 20th 2025

Matthew R. Smith, MD, PhD, discusses findings from the ARANOTE trial that confirm the efficacy of darolutamide plus ADT in mCSPC.

Five Under 5: Top Oncology Videos for the Week of 8/10

August 17th 2025

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

FDA Grants Fast Track Designation to HLD-0915 for Metastatic Castration-Resistant Prostate Cancer

August 14th 2025

HLD-0915 has received fast track designation from the FDA, allowing for more frequent communication with the agency regarding the drug’s candidacy for approval.

Dr Rathkopf on Niraparib Plus Abiraterone Acetate and Prednisone in HRR+ mCSPC

August 13th 2025

Dana E. Rathkopf, MD, discusses the clinical significance of findings from the phase 3 AMPLITUDE trial in HRR gene–mutated mCSPC.

Dr Attard on Niraparib/Abiraterone Acetate Plus Prednisone in mCRPC With HRR Alterations

August 13th 2025

Gerhardt Attard, MD, PhD, FRCP, discusses niraparib plus abiraterone acetate and prednisone in mCSPC with HRR gene alterations.

Final Thoughts: Importance of Treating mCSPC and Preserving Quality of Life

August 13th 2025

Panelists discuss how successful metastatic castration-sensitive prostate cancer (mCSPC) management requires balancing cancer control with quality-of-life preservation, emphasizing the need for better tools to measure patient-reported outcomes, comprehensive survivorship care addressing cardiovascular and bone health, and personalized approaches that help patients understand their prognosis while maintaining their ability to thrive during treatment.

Dr Morgans on Enzalutamide Plus Radium-223 in mCRPC

August 11th 2025

Alicia Morgans, MD, MPH, discusses enzalutamide plus radium-223 in with metastatic castration-resistant prostate cancer.

The OncFive: Top Oncology Articles for the Week of 8/3

August 9th 2025

The FDA grants accelerated approval to zongertinib in lung cancer, clears dordaviprone in glioma, and awards priority review to liso-cel sBLA in MZL.

FDA Accepts NDA for New Formulation of PSMA PET Imaging Agent Piflufolastat F 18 in Prostate Cancer

August 6th 2025

The FDA accepted the NDA seeking the approval of a new formulation of piflufolastat F 18 in prostate cancer.

Weighing HRQOL and Tolerability in Metastatic Castration-Sensitive Prostate Cancer Care

August 6th 2025

Panelists discuss how quality-of-life considerations are paramount in treatment selection for patients with metastatic castration-sensitive prostate cancer (mCSPC), with data showing that achieving ultralow prostate-specific antigen (PSA) levels correlates with better quality-of-life outcomes and that tolerability profiles, particularly regarding fatigue and drug-drug interactions, significantly impact daily patient experience.

Suboptimal PSA Response: What Are the Best Next Steps?

August 6th 2025

Panelists discuss how managing patients with suboptimal prostate-specific antigen (PSA) response or rising PSA requires careful consideration of PSA kinetics, doubling time, duration of prior response, and imaging findings to determine whether to continue monitoring, add therapy, or transition to castration-resistant treatment approaches.

CaRe Prostate Study of INKmune in Metastatic CRPC Hits Primary, Secondary End Points

August 4th 2025

The phase 1/2 CaRe Prostate trial examining INKmune in patients with metastatic CRPC has met its primary and secondary end points.

Consensus Guidelines Needed to Further Optimize PARP Inhibition, Molecular Imaging, and ARPI Use in Prostate Cancer Management

August 4th 2025

Rana R. McKay, MD, expands on key updates and knowledge gaps in prostate cancer management discussed at the Bridging the Gaps in Prostate Cancer meeting.

Revisit Every OncLive On Air Episode From July 2025

July 31st 2025

Read a recap of the episodes of OncLive On Air that debuted in July 2025.

Understanding PSA Threshold in Metastatic Castration-Sensitive Prostate Cancer

July 30th 2025

Panelists discuss how data from the International Registry for Men with Advanced Prostate Cancer (IRONMAN) demonstrates that achieving a prostate-specific antigen (PSA) threshold below 0.2 ng/mL at 6 to 12 months is associated with improved progression-free survival and overall survival regardless of treatment regimen.

PSA Nadir and Response Assessment in Metastatic Castration-Sensitive Prostate Cancer

July 30th 2025

Panelists discuss how prostate-specific antigen (PSA) nadir serves as a crucial prognostic marker in metastatic castration-sensitive prostate cancer (mCSPC), with faster drops to lower levels (particularly below 0.2) correlating with better outcomes, whereas imaging frequency should be customized based on clinical status and PSA kinetics.

Lineage Plasticity and Treatment Resistance Highlight Need for Personalized mCRPC Strategies

July 28th 2025

Jue Wang, MD, outlines how prolonged androgen suppression may drive prostate cancer evolution.

Real-World Treatment Gaps in mCRPC Reinforce the Need for Personalized Selection and Sequencing

July 23rd 2025

Jue Wang, MD, discusses persistent gaps between clinical advances and real-world care and the evolving role of personalized treatment strategies in mCRPC.

Key Takeaways in mCSPC: Combination Therapy and Germline Testing Is the New Standard of Care

July 23rd 2025

Panelists discuss how androgen deprivation therapy (ADT) monotherapy is no longer acceptable for metastatic castration-sensitive prostate cancer (mCSPC), emphasizing that combination therapy with androgen receptor (AR) pathway inhibitors or chemotherapy plus universal germline testing should be the new standard of care.